Clinical Trial

A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

Name: A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants — clinical trial record (NCT06977880)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of MORF-440 administered to healthy participants single-ascending dose (SAD) and maximum ascending dose (MAD) substudy.

Protocol Amendment History 1 change

critical Trial completed 2026-04-18

Trial Details

NCT Number	NCT06977880
Lead Sponsor	Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Conditions	Healthy
Enrollment	80 participants
Start Date	2025-02-19
Primary Completion	2026-03-20 (estimated)
Study Completion	2026-03-20 (estimated)
Updated on ClinicalTrials.gov	2026-04-17